Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: There is a relative lack of research evaluating the outcomes when treatment guidelines or algorithms for psychotic disorders are followed. This systematic review and meta-analysis determined the response rates to antipsychotic medications at different stages of these algorithms and whether these response rates differ in first episode cohorts.

Methods: Data sources: A systematic search strategy was conducted across four databases PubMed, EMBASE, PsycINFO (Ovid) and CINAHL. Studies that had sequential trials of different antipsychotic medications were included. A meta-analysis of proportions was performed using random effects models and sub-group analysis in first episode psychosis studies.

Results: Of the 4078 unique articles screened, fourteen articles, from nine unique studies, were eligible and included 2522 participants. The proportion who experienced a response to any antipsychotic in the first stage of an algorithm was 0.53 (95 % C.I.:0.38,0.68) and this decreased to 0.26 (95 % C.I.:0.15,0.39) in the second stage. When clozapine was used in the third stage, the proportion that achieved a response was 0.43 (95 % C.I. 0.19, 0.69) compared to 0.26 (95 % C.I.:0.05,0.54) if a different antipsychotic was used. Four studies included 907 participants with a first episode of psychosis and the proportions that achieved a response were: 1st stage: 0.63 (95 % C.I.: 0.45, 0.79); 2nd stage: 0.34 (95 % C.I.:0.16,0.55); clozapine 3rd stage: 0.45 (95 % C.I.:0.0,0.97), different antipsychotic 3rd stage: 0.15 (95 % C.I.,0.01,0.37).

Discussion: These findings support the recommendation to have a trial of clozapine after two other antipsychotic medications have been found to be ineffective.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2024.02.035DOI Listing

Publication Analysis

Top Keywords

antipsychotic medications
16
response rates
12
sequential trials
8
trials antipsychotic
8
treatment guidelines
8
psychotic disorders
8
disorders systematic
8
systematic review
8
review meta-analysis
8
episode psychosis
8

Similar Publications

Brexpiprazole is a second-generation antipsychotic with multiple indications, including the treatment of schizophrenia. As a partial dopamine agonist, brexpiprazole differs from most other antipsychotics, yet uncertainties about its full mechanism of action have led to some ambiguity among prescribers. To address this gap, an international panel of psychiatric experts was organized and convened with funding from Otsuka Pharmaceutical Europe Ltd and H.

View Article and Find Full Text PDF

Background: Antipsychotics are associated with side effects like weight gain, obesity, and menstrual disorders in Women, which can reduce treatment compliance and increase cardiovascular, metabolic risks, dementia, and other chronic diseases, as well as increase mortality, and reduce the quality of life in patients. Data on these effects in Vietnam are limited. This study evaluated changes in body weight, BMI, menstrual cycle, and metabolic syndrome components among female schizophrenic inpatients treated with antipsychotics.

View Article and Find Full Text PDF

Background: Neuroimmune processes are often implicated in young people with atypical neuropsychiatric disorders, yet treatment implications remain controversial. This case series details young people with primary psychiatric disorders who received adjunctive immunotherapy after thorough investigation and extensive conventional treatments.

Methods: We evaluated 45 individuals (93% female, ages 12-30 years) with atypical psychiatric presentations suggesting potential neuroimmune involvement.

View Article and Find Full Text PDF

Background: After remission of a first-episode psychosis (FEP), antipsychotic discontinuation is associated with an increased risk of relapse compared to maintenance treatment. We studied short and longer-term effects of discontinuation of D receptor (DR) antagonist and partial agonist antipsychotics on striatal dopamine DR availability in FEP patients.

Methods: Remitted FEP patients underwent two [C]raclopride PET scans to measure striatal DR availability: 1 week after antipsychotic discontinuation (n = 16 antagonist users, n = 6 partial agonist users) and after being medication free for 6-8 weeks (n = 8 antagonist users, n = 5 partial agonist users).

View Article and Find Full Text PDF

Hippocampal subfield activity in schizophrenia: Effects of the disease course.

Schizophr Res

September 2025

Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA. Electronic address:

Alterations in hippocampal structure and function are established in schizophrenia. However, the specific patterns of hippocampal activity along the schizophrenia course remain unknown. Eighty-five study participants [34 schizophrenia probands (SZ), 32 first-degree relatives (REL), 19 healthy controls (HC)] underwent 3Tesla ultra-high resolution brain MRI (Vascular Space Occupancy); relative cerebral blood volume (rCBV)-an index of regional activity-was estimated across hippocampal subfields: dentate gyrus (DG), CA3, CA1, and subiculum (SUB).

View Article and Find Full Text PDF